Podcast Episodes
Back to Search
Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation
Season 7 Episode 399
Speed to patients and cross-border collaboration dominated conversations at London Life Sciences Week, even as investors on both sides of the Atlanti…
1 day, 6 hours ago
Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
Season 7 Episode 398
J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for we…
4 days, 22 hours ago
Ep. 397 - What the U.S. midterms mean for biopharma
Season 7 Episode 397
Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipart…
1 week, 4 days ago
Ep. 396 - China’s first-order innovation
Season 7 Episode 396
Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment re…
2 weeks ago
Ep. 395 - ESMO analysis & Auchincloss proposal
Season 7 Episode 395
A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation l…
2 weeks, 4 days ago
Ep. 394 - Security concerns in U.S., China reshaping biotech
Season 7 Episode 394
Proposed U.S. Treasury rules implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotech…
3 weeks, 4 days ago
Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
Season 7 Episode 393
Roche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfron…
1 month ago
Ep. 392 - Biotech markets: Pause before the storm?
Season 7 Episode 392
An M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling so…
1 month, 1 week ago
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
Season 7 Episode 391
Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets …
1 month, 2 weeks ago
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
Season 7 Episode 390
Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Round…
1 month, 3 weeks ago